HR Execs on the Move

ST CATHRINE REGINAL HOSP

www.stchc.com

 
Saint Catherine Medical Center Fountain Springs is committed to establishing itself as a center of clinical excellence, the preferred medical center for residents of our region and for physicians to practice, and the regional employer of choice. This
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.stchc.com
  • 2200 Market St
    Charlestown, IN USA 47111
  • Phone: 812.256.3301

Executives

Name Title Contact Details

Similar Companies

Boehringer Laboratories

Boehringer Laboratories, LLC. is a family owned American medical technology company with headquarters in Phoenixville, Pennsylvania.

Gandara Center

Gándara was established in 1977 by a doctor named Jose Gándara, of Puerto Rican descent who sought to provide mental health services to the growing and largely Hispanic community in Holyoke, Massachusetts. Recently the Gándara Center expanded services ...

Purdue Pharma L.P.

Purdue Pharma LP is a privately held pharmaceutical company founded by John Purdue Gray.

Marker Therapeutics

We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.

True Health

True Health (formerly Central Florida Family Health Center) is a non-profit patient-centered medical home that has been serving the Central Florida community since 1977. Our centers, conveniently located throughout Central Florida, aim to bring you ...